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Preface 
This documentation report describes a project carried out by QSAR researchers from the National 
Food Institute, Technical University of Denmark (DTU). In the project QSAR models have been 
applied to screen REACH substances for potential CMR properties. The substances screened were 
either not registered by the deadline in 2010 or have been registered but not classified for CMR 
properties.  
 
The project participants from DTU were: 
Eva B. Wedebye, Jay R. Niemelä, Nikolai G. Nikolov, and Marianne Dybdahl. 
 
The project steering group members were besides the participants from the DTU also Henrik Tyle 
and Magnus Løfstedt, both from the Danish Environmental Protection Agency (EPA). 
 
The project was financed by the Danish EPA. 
 
The report reflects the author’s views and opinions but not necessarily views and opinions of the 
Danish EPA. 
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Summary and Conclusion 
In the European chemicals legislation, REACH /1/, the first deadline for registration was the 1st 
December 2010. At this deadline, pre-registration substances (PRS) living up to at least one of a 
number of criteria in REACH articles should be registered. The criteria in REACH art. 12(1) specify 
that substances classified as carcinogenic, mutagenic or toxic to reproduction (CMR) in category 1 
or 2 according to Directive 67/548/EEC /2/, and manufactured in or imported into the EU in 
quantities of 1 tonne or more per year per manufacturer or per importer, should be registered. Of 
the 143,835 PRS, 5,705 substances were according to the European Chemicals Agency, ECHA, 
registered per 15th June 2012 and the published part of the list was available as a downloadable file 
on ECHA’s homepage /3/. 
 
However, earlier studies have shown that a very large fraction of the high tonnage industrial 
substances on the EU market have few or no experimental test data /4/. As a result, substances 
presently used in the EU with CMR properties, may not have been recognized, and consequently not 
self-classified for CMR and registered under REACH. Furthermore, registered substances with 
unrecognized CMR properties may similarly not have been suggested classified for CMR effects. 
 
Because experimental determination of toxicity requires resources both in terms of cost and time, 
reliable in silico alternatives such as quantitative structure-activity relationship (QSAR) models are 
becoming important tools for rapid and cost-effective predictions of toxic effects. In this project 
QSAR models were used to screen REACH substances for potential CMR properties. The individual 
models applied are according to validation results able to predict the individual endpoints with 
accuracies (overall concordances) of approximately 70-85 percent, with most of the models having 
considerably higher specificity than sensitivity.  
 
Model predictions from different models for relevant tests were combined to reach overall CMR 
calls. The QSAR model prediction algorithms used for C or M calls require positive predictions from 
more than one of the included QSAR models. This may theoretically reduce “noise” (i.e. 
erratic/erroneous occurrence of data which are inconsistent when evaluated across related test 
endpoints or test systems) and increase accuracy in the overall call. For C the screening was limited 
to genotoxic carcinogens and for R only certain types of mechanisms causing malformation or fetal 
mortality were included. This means that non-genotoxic carcinogens or reproductive toxicants 
having other types of effects were not covered in the screening. 
 
QSARs were applied to screen for CMR effects for: 
1. Substances registered in 2012 that are not self-classified by industry as C and/or M and/or R. 
2. Pre-registered substances which were not registered in 2012, possibly due to unrecognized CMR 
properties based on lack of test data. 
 
QSAR-based CMR screenings were applied for REACH substances where structure information was 
available; 1,066 substances registered under REACH by 2012 and 67,656 PRS not registered were 
screened. For the non-registered substances information from the Nordic substance register 
database (SPIN) was used to identify substances for which human exposure is likely to be 
significant. 
 
Within the constraints of the project it was chosen to provide a more thorough analysis on a few 
manually selected substances for which supporting information was also taken into consideration. 
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This included a quick check of possible readily available existing experimental CMR information on 
the eChemPortal website. Furthermore, the in-house Danish QSAR prediction database was taken 
into account for a more holistic evaluation of the individual substances. The database contains 
predictions for many endpoints covering physical-chemical properties, bioavailability, CYP P450 
metabolism, eco-toxicity and human health endpoints (mainly effects in rodents measured by 
standardized laboratory tests. 
 
The screening resulted in the following numbers of REACH substances predicted by QSAR to 
potentially have CMR properties: 
1. Non-registered substances in 2012; 18,266 
2. Non-registered substances in 2012 with likely significant human exposure; 695 
3. Non-registered substances in 2012, with exposure information and manually selected; 26 
4. Registered substances (of which some may be classified for CMR); 212 
5. Registered substances not classified for CMR (by a harmonized classification or by a self-
classification of the REACH registrant), manually selected; 5 
 
The resulting lists of substances with predicted CMR properties were generated with the aim that 
the Danish EPA can use them as a tool for prioritizing substances for further work.  
 
It is important to note that the substances mentioned in this report have not proven to meet the 
criteria for carcinogenicity, mutagenicity or reproductive toxicity. Nor has it been proven that their 
use constitute a risk to consumers or workers. Further work needs to be carried out including expert 
assessment of all available relevant information for each substance before a conclusion on their 
CMR properties can be made. 
 
For the registered substances (point 4) a further expert evaluation can be undertaken in relation to 
the prioritization of substances for the CoRAP list (the EU list of registered substances, which are 
examined to clarify suspicion about effects of concern). This prioritization takes place once a year 
and is done by the European Chemicals Agency (ECHA) in cooperation with the member states. 
 
For the non-registered substances with likely significant human exposure (point 2), the QSAR 
results from this exercise can be applied to flag to Industry, that there may be a need to obtain more 
knowledge in order to document a safe use (depending on which available documentation already 
exists). 
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Sammenfatning 
Den første frist for registrering under den europæiske kemikalielovgivning REACH /1/ var den 1. 
december 2010. Denne dato skulle alle såkaldte præ-registreringsstoffer (PRS) som lever op til visse 
kriterier registreres. Ifølge REACH art. 12(1) skulle blandt andet stoffer som er klassificeret som 
kræftfremkaldende, mutagene eller toksiske for reproduktionen (CMR) i kategori 1 eller 2 ifølge 
Direktiv 67/548/EEC/2, og som produceres eller importeres i EU i mængder på 1 ton eller mere per 
år per producent eller importør registreres. Af de 143.835 PRS var 5.705 kemiske stoffer per 15. juni 
2012 blevet registreret ifølge det Europæiske Kemikalieagentur ECHA, og den publicerede del af 
listen var tilgængelig på ECHA’s hjemmeside /3/. 
 
Tidligere studier har imidlertid vist, at en meget stor andel af højtonnage industrikemikalierne på 
markedet i EU har mangelfulde eller ingen eksperimentelle data /4/. Konsekvensen af dette er, at 
nogle CMR stoffer anvendt i EU muligvis ikke er blevet erkendte som havende disse egenskaber og 
dermed ikke er blevet selv-klassificeret for CMR og registreret under REACH. Endvidere er 
registrerede høj-tonnage stoffer med ikke erkendte CMR egenskaber højst sandsynligt ikke blevet 
foreslået klassificeret for CMR effekter. 
 
Eksperimentel undersøgelse af toksicitet kræver ressourcer både i form af tid og penge, og derfor er 
pålidelige in silico alternativer som for eksempel QSAR (quantitative structure-activity relationship) 
modeller blevet vigtige værktøjer i forbindelse med hurtige og omkostningseffektive forudsigelser af 
toksiske effekter. I dette projekt blev QSAR modeller brugt til at screene REACH stoffer for 
potentielle CMR egenskaber. Modellerne anvendt i projektet for de individuelle effekter har ifølge 
valideringsresultater overordnede nøjagtigheder på omkring 70-85%, hvor de fleste af modellerne 
har en betydeligt højere specificitet end sensitivitet.  
 
Modelforudsigelser fra forskellige modeller for relevante tests blev kombineret i QSAR model 
algoritmer der mundede ud i overordnede CMR meldinger. Algoritmerne for C og M kræver positive 
forudsigelser fra mere end én af de inkluderede QSAR modeller. Dette kan teoretisk reducere ”støj” 
(tilfældig/fejlagtig forekomst af data som er inkonsistente når der evalueres på tværs af relaterede 
effekter eller test systemer) og forhøje nøjagtigheden i den overordnede melding. For C var 
screeningen begrænset til genotoksiske kræftfremkaldende stoffer og for R var kun visse typer af 
mekanismer der giver misdannelser eller fosterdød inkluderet. Dvs. at ikke-genotoksiske 
kræftfremkaldende stoffer og reproduktions-toksiske stoffer med andre typer af effekter ikke var 
inkluderet i screeningen. 
  
QSAR modellerne blev anvendt til screening af CMR effekter for: 
1. Stoffer registreret per 2012, men ikke selv-klassificeret af industrien som C og/eller M og/eller R. 
2. Præ-registrerede stoffer som ikke var registrerede i 2012 muligvis på grund af ikke erkendte CMR 
egenskaber forårsaget af mangel på test data. 
  
QSAR baserede CMR screeninger blev anvendt på REACH stoffer for hvilke struktur information 
var tilgængelig; 1.066 stoffer registreret under REACH per 2012 og 67.656 PRS blev inkluderet i 
screeningen. For de ikke registrerede stoffer blev information fra den nordiske stofregister-database 
(SPIN) desuden anvendt til at identificere stoffer med potentiel human eksponering. 
 
I det omfang projektet tillod det, blev et begrænset antal manuelt udvalgte stoffer underlagt en 
mere grundig analyse, hvor også supplerende information blev inddraget. Dette inkluderede en 
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hurtig gennemgang af mulig tilgængelig eksisterende eksperimentel CMR information på 
eChemPortal hjemmesiden. Desuden blev den danske in-house QSAR database, som indeholder 
forudsigelser for mange effekter såsom fysisk-kemiske egenskaber, biotilgængelighed, CYP P450 
metabolisme, øko-toksicitet og humane sundhedseffekter (primært effekter målt i gnavere og udført 
efter standardiserede dyreforsøgs-protokoller), anvendt for at give en mere holistisk evaluering af 
de individuelle stoffer.  
 
Screeningen resulterede i følgende antal af REACH stoffer med potentielle CMR egenskaber 
forudsagt ved hjælp af QSAR: 
 
1. Ikke registrerede stoffer i 2012; 18,266 
2. Ikke registrerede stoffer i 2012 med signifikant human eksponering; 695 
3. Ikke registrerede stoffer i 2012 med eksponeringsinformation og manuelt udvalgt; 26 
4. Registrerede stoffer (hvoraf nogle muligvis er klassificeret for CMR); 212 
5. Registrerede stoffer ikke klassificerede for CMR (ved harmoniserede klassificeringer eller 
selvklassificeringer af REACH registranten), manuelt udvalgt; 5 
 
De resulterende lister over stoffer med forudsagte potentielle CMR egenskaber blev genereret med 
det formål at Miljøstyrelsen kan bruge dem fremadrettet som et redskab til at prioritere indsatsen i 
forhold til kemiske stoffer. 
 
Det er vigtigt at understrege, at det ikke er bevist at stofferne på listerne har kræftfremkaldende, 
mutagene eller reproduktions-toksiske effekter. Ligeledes er det heller ikke bevist at brugen af dem 
udgør en risiko for arbejdstagere eller forbrugere. Yderligere arbejde, der omfatter 
ekspertvurderinger af al relevant tilgængelig information for de enkelte stoffer, skal udføres før en 
konklusion omkring deres potentielle CMR egenskaber kan drages. 
 
For de registrerede stoffer (punkt 4) kan en yderligere ekspertvurdering foretages i forbindelse med 
prioritering af stoffer til CoRAP listen (EU liste over registrerede stoffer, der skal undersøges 
nærmere med henblik på at afklare mistænkte bekymrende effekter). Denne prioritering finder sted 
en gang om året og foretages af det Europæiske Kemikalieagentur (ECHA) i samarbejde med 
medlemslandene. 
 
For de ikke-registrerede stoffer med eksponering (punkt 2) kan QSAR resultaterne fra denne 
undersøgelse bruges som et signal til Industrien om, at der kan være behov for fremskaffelse af 
mere viden for at dokumentere sikker brug (afhængigt af, hvilken anden dokumentation der 
allerede foreligger). 
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Introduction 
Background 
According to the chemicals legislation in the EU, REACH, all CMR substances (Carcinogenic, 
Mutagenic, or toxic to Reproduction) produced or imported in more than 1 tonne per year should be 
registered by 1 December 2010. The same applies according to REACH art. 23 to vPvB/PBT- (very 
Persistent very Bioaccumulating / Persistent, Bioaccumulating and Toxic) substances and 
substances classified as very toxic to aquatic organisms which may cause long-term adverse effects 
in the aquatic environment (R50/53) above 100 tonnes per year, and finally to all high production 
volume substances (>1000 tonnes per year per EU producer/importer) regardless of their 
hazardous properties.  
 
However, earlier studies /4/ of the previous list of existing industrial substances in the EU, the so-
called EINECS list, have shown that for the majority of the EINECS high production volume 
substances there were insufficient or no test data about their CMR properties. For the less-than-
high tonnage substances there is likely to be even less test data about their CMR properties.  
 
With the new REACH pre-registration list (PRS), the number of industrial substances in the EU has 
grown from 100,206 EINECS substances to potentially 143,835 substances. It is to be expected that 
for this new list, which includes the full EINECS list, there may be many substances with 
insufficient or no experimental results on CMR properties. 
 
Due to the lack of test data on CMR properties, unrecognized CMR substances presently used in the 
EU in tonnages above 1 tonne and less than 1000 tonnes per year per importer/producer may with 
high probability not have been registered under REACH as foreseen by the legislation. 
 
The Advisory self-classifications list /5-8/based on QSARs and published by the Danish 
Environmental Protection Agency (2001, 2009, 2010) indicates that there may be a substantial 
number of the substances on the EINECS list, and consequently on the PRS list, with non-
recognized CMR properties.  
 
Aim 
The aim of the project was to generate working lists of relevant substances with potential CMR 
properties, which can be used by the Danish EPA as a tool for prioritizing substances for further 
work. For the generation of the working lists QSARs were applied to screen for potential CMR 
properties. See annex 1 for a general introduction to QSARs and annex 4 for the QSAR models used. 
Where structural information for discrete organic substances was available, QSAR models were 
applied to screen for CMR properties for REACH substances, which were either not registered or 
which were registered but not classified for CMR properties. Furthermore, information from the 
Nordic substance register database (SPIN) was used to identify substances where human exposure 
is likely to be significant. 
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QSAR screening and results 
An overview of the steps and resulting numbers of selected substances in the project is given in 
Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Total number of pre-registered substances. Of these, the registered part (4,303 substances according to an EC 
number comparison) is treated separately in the right side of Figure 1 
** Publishable registered chemicals from ECHA homepage, downloadable file as of 15th June 2012 
 
Figure 1 Overview of the project flow 
 
Initial lists 
The initial lists for the screening were the ECHA list of registered substances as of 15th June 2012 
with 5,705 registered substances of which 5,306 were publishable /3/, and the ECHA pre-
registration list with 143,835 substances, which were pre-registered (PRS) between 1 June and 1 
December 2008 /10/.  
 
Selection of structures for QSAR screening (step 1 in Figure 1) 
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To make the QSAR screening as comprehensive as possible it should be performed on as many as 
possible of the substances on the two initial lists. A prerequisite for making predictions with the 
QSAR software is that structural information in the format of e.g. SMILES or sdf representation is 
available, and that it is discrete organic substances.  
 
As structural information was not required as part of the pre-registration and as no formal structure 
set on the PRS from ECHA exists, other sources for the structural information were searched. The 
Computational Toxicology Group within the EC Joint Research Centre (JRC) has generated 
structure information for as many as possible of the PRS by using the ACDLabs Name-To-Structure 
software and validated them with a random sample /9/. In total 80,413 structures were generated, 
including discrete organics, inorganics /organometallics etc.  
 
The remaining around 60,000 PRS not included in the JRC list may be e.g. discrete organic 
structures where structure information could not be retrieved or UVCB’s (substance of Unknown or 
Variable composition, Complex reaction products or Biological materials, e.g. extracts from plants, 
which are only suitable for QSAR analysis if the individual components are identified). 
 
Of the 80,413 structures on the JRC list, 70,983 substances could be applied in the QSAR screening 
software used in this project. Of these, 1,545 were on ECHA’s list of “Publishable Substances 
Registered as of 15-Jun-2012” with a total of 5,306 published entries, and the remaining 69,438 
were PRS, which were not registered. See Annex 2 for a description of the preparation of the JRC 
structure set for this project.  
 
Removal of substances with EU harmonized classification (step 2 in figure 1) 
Substances with EU harmonized classifications on Annex VI to Regulation (EC) No 1272/2008 /11/ 
including ATP1, and Annex I to Directive 67/648/EEC /12/ including ATP 31 were removed by 
applying a CAS number comparison. This comparison included, where information was available, 
also group expansions for group entries. However, as there is no official exhaustive CAS list of all 
substances covered by the group entries in Annex VI, and because a substance may have more than 
one CAS number, a few substances with EU harmonized classifications may not have been removed 
in this step.  
 
A total of 1,066 REACH registered substances and 67,656 PRS not registered remained for 
processing. 
 
CMR classification filter; removal of substances with industry CMR self-
classifications (step 3 in figure 1) 
REACH registration dossiers for the 1,066 substances were downloaded from the ECHA website 
(for some substances multiple dossiers), and the CMR classification information was extracted from 
these. The classifications in the dossiers may be harmonized EU classifications or they may be self-
classifications. Step 2 filtered out all the EU harmonized classified substances listed with CAS 
numbers but there may be chemicals in the 1,066 list covered by harmonized classification group 
entries. From the 1,066 substances there were 97 substances having at least one CMR R-phrase 
(R40, R45, R46, R49, R60, R61, R62, R63 or R68). (It can be mentioned in parentheses that of the 
97 substances having a CMR classification in the registration dossier, there were 48 which were 
predicted to be C, M and/or R by the QSAR screen applied in step 4).  
 
A total of 969 REACH registered substances remained for processing.  
 
As an additional exercise, all PRS having one or more self-classifications for C, M or R notified from 
one or more manufacturers/importers were downloaded from the ECHA C&L Inventory database 
/13/. Out of the 70,983 JRC substances which could be applied in the QSAR screening 2,239 (3.2%) 
had one or more self-classifications for C, M or R in ECHAs database. Of the substances predicted 
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in step 4 to have CMR properties (for not registered substances 18,266 substances and for 
registered substances 212 substances) there were 753 (4.1%) not registered and 31 (14.6%) 
registered substances with one or more Industry notified self-classifications for C, M or R.  
 
Selection of CMR predicted substances (step 4 in figure 1) 
The resulting lists of substances were submitted to MultiCASE (version 2.3.0.37) for generation of 
QSAR predictions for all relevant endpoints. The QSAR predictions from the individual models 
were integrated by decision algorithms for C-, M- and R- classification. These algorithms were also 
used in the development of the Danish Advisory self-classification list /7,8/. 
 
The following commercial or in-house DTU QSAR models have been applied in the screening: 
 
 Reverse mutation test, Ames in vitro 
 Chromosome aberration in CHO in vitro 
 Chromosome aberration in CHL in vitro  
 Mouse lymphoma cell gene mutation test in vitro 
 Sex-Linked Recessive Lethal test in Drosophila melanogaster in vivo (indicator test for 
structural chromosome aberration) 
 Comet assay in mouse in vivo (indicator test for DNA damage/mutation) 
 Sister chromatid exchange assay in mouse bone marrow in vivo (indicator test for structural 
chromosome aberration) 
 Rodent dominant lethal test in vivo (indicator test for structural chromosome aberration) 
 Mouse mammalian bone marrow erythrocyte micronucleus test in vivo (test for structural 
chromosome aberration) 
 FDA Cancer models male/female Rat and male/female Mouse and RCA methodology 
 Teratogenic potential in humans in vivo (based on epidemiological, clinical and animal data for 
drugs) 
 
The models applied are according to validation results able to predict the individual endpoints with 
overall concordances of approximately 70-85 percent. See Annex 3 for an introduction to the 
MultiCASE software, and Annex 4 for technical information on the individual models. 
 
Predictions from all the applied models for the full lists of substances were integrated into the Oasis 
DatabaseManager program, in which the screenings were performed according to the algorithms 
described below. 
 
QSAR screening algorithm for genotoxic carcinogenicity 
QSAR models for four carcinogenicity in vivo endpoints and three genotoxicity in vitro endpoints 
were included in the screening performed according to the scheme illustrated in Figure 2.  
 
 
 
Figure 2 QSAR screening scheme for genotoxic carcinogenicity 
 
The criterion for a positive cancer prediction is that there is a positive prediction according to the 
RCA methodology (previously denoted ICSAS) /14/, corresponding to two or more positive 
carcinogenicity predictions (within the applicability domain, AD, defined in the validation) with 
certain additional consistency requirements, and accepting only predictions for substances without 
significant deactivating fragments. If, for an evaluated substance, one or more positive experimental 
tests was present as part of the training sets for the models for any cancer endpoint, this took 
precedence over model predictions. 
 
The genotoxicity criterion is a positive prediction (within the AD defined in the validation) from one 
or more of the models for the following in vitro genotoxicity endpoints; Reverse mutation test 
(Ames), chromosomal aberrations (CHO/CHL), or mutations in mouse lymphoma. 
 
It is noted that the QSAR prediction algorithm used for the carcinogenicity call was restricted to 
genotoxic carcinogenicity. Hence this QSAR based carcinogenicity call did not address non-
genotoxic carcinogens.  
 
QSAR screening algorithm for mutagenicity 
Five models predicting genotoxicity in vivo endpoints are included in the screening which is 
performed according to the scheme illustrated in Figure 3.  
 
 
 
 
Genotoxicity screening 
 
Predictions from models for in vitro 
 
• Reverse mutation test (Ames) 
• Chromosome aberration (CHO/CHL) 
• Mouse lymphoma 
 
 
Positive prediction or  
positive experimental test  
in at least one model 
 
Genotoxic carcinogen 
 
Assessment of carcinogenicity 
 
Predictions from models for in vivo 
 
• Carcinogenicity, male rat 
• Carcinogenicity, female rat 
• Carcinogenicity, male mouse 
• Carcinogenicity, female mouse 
Positive prediction according to 
the FDA RCA method, or positive 
experimental test 
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Figure 3 QSAR screening scheme for mutagenicity 
 
The suggested criterion for a positive mutagenicity prediction is that there is a positive prediction 
(within the AD defined in the validation) in two or more models, accepting only predictions where 
no significant deactivating fragments were detected. If one or more positive tests could be seen (as 
part of the training sets for the models) for any genotoxicity endpoint, this took precedence over 
model predictions. 
 
QSAR screening algorithm for prenatal developmental toxicity 
Three models predicting in vivo teratogenicity or fetal lethality related endpoints have been 
included in the screening which was performed according to the scheme illustrated in Figure 4.  
 
 
Figure 4 QSAR screening scheme for developmental toxicity. 
 
The suggested criterion for a positive developmental toxicity prediction is a positive prediction 
(within the AD defined in the validation) in any of the three models and without a negative 
prediction in the teratogenic potential in humans model.  
 
 
 
Assessment of mutagenicity  
Models for in vivo 
 
 Drosophila melanogaster SLRL 
 Mouse micronucleus 
 Rodent dominant lethal 
 Mouse sister chromatid exchange 
 Mouse Comet 
 
Positive prediction in at least two 
models or positive experimental 
test in at least one model  
Mutagen 
 
 
 Assessment for developmental toxicity  
 
Predictions from models for in vivo 
 
 Teratogenicity, human 
 Drosophila melanogaster SLRL  
 Rodent dominant lethal 
Positive prediction or test in at 
least one endpoint and not 
predicted or tested negative for 
teratogenicity 
Developmental toxicant 
The QSAR models applied cover certain but far from all types of harm to the unborn child; only 
certain types of mechanisms causing malformation or fetal mortality are covered. Many other types 
of reproductive toxicity effects are known to exist – and many reproductive toxicity modes of action 
are currently unknown. Fertility as a reproductive toxicity endpoint was not covered. 
 
A total of 212 REACH registered substances and 18,266 PRS not registered were flagged in this 
process with QSAR predictions for cancer and/or mutagenicity and/or teratogenicity and were 
further processed. 
 
SPIN filter; exposure filter using SPIN information for substances not REACH 
registered (step 5 in figure 1) 
To estimate the human exposure relevance of the identified CMR predicted substances, information 
from the Nordic substance register database (SPIN) was applied. The SPIN database contains non 
confidential information on the use of substances in products in the Nordic countries and is based 
on data from the product registers in Norway, Sweden, Denmark and Finland /15/. 
 
As SPIN registrations are not required for articles, foodstuffs, cosmetics, medicinal products and 
substances imported/produced in quantities less than 100 kg/year per company, substances not 
flagged in SPIN as having human exposure relevance according to the Use Index, may still have 
potential human exposure relevance. Another limitation is that only chemicals used in the 
workplace are registered. Also, SPIN only covers use in the Nordic countries and not the whole EU. 
Vice versa, substances which according to SPIN have human exposure relevance may no longer be 
on the EU market as the information in SPIN is based on previous year’s information in the national 
product registers. Requirements to report and update the information in the national product 
registers are also not identical, and information is not updated every year in all the registers. 
 
Substances having at least one of the following SPIN parameters defined regarding use in the 
Nordic countries; Total Amount in tonnes, Total number of products or Range of use were 
submitted for further processing.  
 
In addition, the Use Index for consumers from the Exposure toolbox of the SPIN database was 
required to be greater than or equal to 3, indicating a potential for direct exposure to humans. The 
Use Index in SPIN is an index by which exposure relevant information, of which a large proportion 
is confidential in the Nordic national registers, can be made publicly available in SPIN. The Use 
Index cannot be used to provide exact quantifications on exposure but is an indicative screening 
tool.  
 
A total of 695 substances were selected. 
 
Manual selection of cases for illustration for registered and not registered substances 
(step 6 in figure 1)  
Within the constraints of the project it was chosen to focus on a few substance cases for illustration. 
The purpose was not to make comprehensive expert judgments on all the obtained QSAR prediction 
profiles for the 695 non-registered substances and the 212 registered substances, but to select a 
number of cases to illustrate how additional available information may be taken into consideration.  
 
For the selected substances, the individual C, M and/or R predictions for key endpoints were 
further inspected manually to take the training set data and biophore statistical information into 
account. Other sources of QSAR information were also consulted, e.g. predictions from a number of 
Leadscope models and the PASS system for CMR properties.  
 
Furthermore, the in-house Danish QSAR prediction database containing predictions for many 
endpoints covering physical-chemical properties, bioavailability, CYP P450 iso-enzyme affinity or 
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inhibitory effects, eco-toxicity and human health endpoints was consulted for a more holistic 
evaluation of the individual substances. 
 
Finally, the eChemPortal webpage was consulted to look for possible experimental CMR related 
information and a quick search on Google was done to find readily available information on the 
occurrence and use of the substances. For the registered substances the online ECHA database with 
registration dossiers was furthermore consulted to see the contained experimental data /3/. 
 
A list with 26 non-REACH-registered substances and a list with 5 REACH registered substances, 
both containing substances with probable significant human exposure potential and for which 
potential CMR properties were predicted, have been compiled. These lists illustrate how further 
evaluation of initially identified potential CMR substances with probable significant human 
exposure potential may be further evaluated for further priority setting. Such further priority setting 
may be used as basis for selecting substances for proposal for (harmonized) CMR-classification and 
/ or for inclusion on the CORAP list (for targeted further confirmatory testing of CMR properties). 
The lists with selected illustrative cases are included in annex 5 and 6. 
 
The resulting lists 
The screening project resulted in the following lists of substances QSAR predicted to potentially 
have CMR properties: 
1. QSAR CMR predicted PRS not registered in 2012: total list of 18,266 
2. QSAR CMR predicted PRS not registered in 2012 with SPIN information on potential 
human exposure: total list of 695 
3. QSAR CMR predicted PRS not registered in 2012, selected illustrative cases: 26 
4. QSAR CMR predicted registered substances: 212 
5. QSAR CMR predicted registered substances not classified for CMR (by a harmonized 
classification or by a self-classification of the REACH registrant), selected illustrative 
cases: 5 
 
The lists are available as follows: 
 
1. List 1_QSAR CMR predicted PRSnot registered in 2012: downloadable at www.mst.dk 
2. List 2_ QSAR CMR predicted PRS not registered in 2012 with SPIN information on 
potential human exposure: downloadable at www.mst.dk 
3. List 3_ QSAR CMR predicted PRS not registered in 2012, illustrative cases: available in 
Annex 5. 
4. List 4_ QSAR CMR predicted registered substances: downloadable at www.mst.dk 
5. List 5_ QSAR CMR predicted registered substances, illustrative cases: available in Annex 6. 
 
It is important to note that the substances in these lists were not proven to meet the criteria for 
carcinogenicity, mutagenicity or reproductive toxicity. Nor has it been proven that their use 
constitutes a risk to consumers or workers. Further work needs to be carried out including expert 
assessment of all available relevant information for each substance before a conclusion on their 
CMR properties can be made. 
 
These lists may be applied by the Danish EPA for prioritization purposes with the proper 
consultation of relevant sources to obtain possible experimental testing information on CMR 
properties of the substances. 
  
Use of the lists 
The results only represent positive predictions. No distinction has been made between a negative 
prediction for an endpoint, and an unreliable prediction (prediction outside the applicability 
domain of the model), which was simply discarded.  
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Evaluated substances which are not on the list, or substances which are on the list but without flags 
for either C, M or R, may have been predicted as not having this / these property(ies), or the models 
may not have been valid for this substance, i.e. predictions were outside the applicability domain for 
these models.  
 
The lists represent QSAR-based identifications of possible CMR hazardous properties of the 
included substances; although SPIN information was taken into account to select chemicals with 
probable significant human exposure no attempt was made to evaluate the actual risk that the 
substances constitute in their current use in the EU. 
 
The duty to map available information on substances lies with manufacturers / importers. The 
models applied in this project had according to validation results accuracies of approximately 70-
85%. Substances appearing on the resulting lists may have experimental test results which are more 
reliable.  
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Annex 1 Short introduction to 
QSARs 
Structure-activity relationships (SARs) and quantitative structure-activity relationships (QSARs), 
collectively referred to as QSARs, are mathematical models that can be used to predict the physico-
chemical, biological (e.g. toxicological) and environmental fate properties of molecules based on 
their chemical structure. “A QSAR is a mathematical model (often a statistical correlation) relating 
one or more quantitative parameters derived from chemical structure to a quantitative measure of a 
property or activity (e.g. a (eco)toxicological endpoint). QSARs are quantitative models that yield 
either a continuous or categorical (yes/no) result” /16/. 
A QSAR model thus links information on the chemical structure of compounds with a specific 
property, and is subsequently used for predicting the same property for unknown compounds. 
Reliable predictions can be obtained for compounds that are within the domain of the developed 
QSAR model, i.e. for compounds that are sufficiently structurally similar to the compounds used to 
train the model. QSAR models are thus powerful tools for predicting chemically induced adverse 
effects and thus for filling data gaps. 
 
The reliability of QSAR-predictions depends on numerous parameters relating to the mathematical 
methods used, the number and precision of the underlying data used for developing the model and 
how suitable the model is for the particular substance. In general the uncertainty of QSARs is 
caused predominantly by two different reasons: a) the inherent variability of the input data used to 
establish the model (training set); and b) the uncertainty resulting from the fact that a model can 
only be a partial representation of reality (in other words does not model all possible mechanisms 
concerning a given endpoint and does not cover all types of substances). However, as a model 
averages the uncertainty over all substances, it is possible for an individual model estimate to be 
more accurate than an individual measurement /16/.  
 
Validation is a trial of the model performance for a set of substances independent of the training set, 
but within the domain of the model. The model predictions for these substances are compared with 
measured endpoints for the substances in order to establish the predictive performance of the 
model. Ideally all models should be assessed by checking how well they predict the activity of 
substances, which were not used to make them. This is, however, not always simple. In part 
valuable information may be left out by setting aside substances to be used in such an evaluation, 
and in part it can be extremely difficult to assess how “external” substances relate to the model’s 
domain; that is, if they represent a random distribution within this applicability domain and 
thereby giving a fair picture of the predictive performance of the model.  
 
This problem is often addressed by using one or another form of cross-validation, where a number 
of partial models are “externally validated” by dividing the training set into a reduced training set 
and a testing set. The reduced training set is used to develop a partial model, while the remaining 
data are used as a test set to evaluate the model predictivity. This is repeated a number of times and 
the results are used to calculate the predictivity measures for the models; for quantitative 
(continuous) models in the form of Q2 and SDEP (standard deviation error of prediction), and for 
qualitative (categorical yes/no) models in the form of sensitivity (ability to correctly predict 
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positives), specificity (ability to correctly predict negatives) and concordance (overall accuracy, see 
also e.g. /16/ and /17/ for further details). In the majority of validations carried out on the models 
applied in this project the stable leave-many-out (LMO) cross-validation approach was used. The 
training set was split by random (however keeping the positive / negative balance in the subsets) 
into two portions of 50% of the substances, models on each of the reduced sets were made, and the 
one model was run to predict the training set of the other model and the other way around, 
repeating this 5 times. Leaving out 50% of the substances in the partial validation models is a large 
perturbation of the training set, which generally leads to realistic, and often pessimistic, measures 
of the predictivity of the model. The commercial cancer were also validated by external validation.  
 
Concordance will vary depending on both the method used, and the endpoint in question. In 
general, contemporary QSAR systems can often correctly predict the activity of about 70 – 85% of 
the substances examined, provided that the query structures are within the domains of the models.  
 
When applying QSAR’s it is important to assure that an obtained prediction falls within the 
applicability domain (AD) of the models i.e., that there is sufficient similarity (in relevant 
descriptors) between the query substance and substances in the training set of the model. There is 
no single and absolute applicability domain for a given model /16/. Generally, the broader the 
applicability domain is defined the lower predictivity can be expected. The applicability domain 
should be clearly defined and the validation results should correspond to this defined domain, 
which is again used when the model is applied for predictions. 
QSARs tools are used more and more by authorities e.g. in the US and the EU, as well as by 
industry, to assess physico-chemical, (eco-)toxicological, ADME, MoA, and environmental fate 
properties of substances.  
 
In the new EU chemicals legislation, REACH, all other options, including use of (Q)SARs, should be 
considered before performing (or requiring) vertebrate testing /1/. Annex XI of REACH contains 
the following wording regarding (Q)SARs:  
 
Results obtained from valid qualitative or quantitative structure-activity relationship models 
((Q)SARs) may indicate the presence or absence of a certain dangerous property. Results of 
(Q)SARs may be used instead of testing when the following conditions are met:  
  
Results are derived from a (Q)SAR model whose scientific validity has been established,  
 
The substance falls within the applicability domain of the (Q)SAR model,  
 
Results are adequate for the purpose of classification and labelling and/or risk assessment, and,  
 
Adequate and reliable documentation of the applied method is provided.  
Use of QSAR to identify potential CMR substances of relevance under the REACH regulation 21 
 
Annex 2 Structure set 
preparation for QSAR 
screening 
 
It is a prerequisite for using QSAR software to generate predictions that structural information in 
the format of e.g. SMILES or sdf is available. As structural information was not required as part of 
the pre-registration and as no formal structure set on the PRS from ECHA exists, other sources for 
the structural information were searched. 
 
The Computational Toxicology Group within the Joint Research Centre (JRC) has generated 
structure information for PRS by using the ACDLabs Name-To-Structure software and validated 
them with a random sample /9/. In total 80,413 structures were generated, including both discrete 
organics, inorganics etc. 
 
The SDF records of the original Daginnus set were converted into an OASIS Database Manager 
database using OASIS Database Manager 1.7.3 and removing the small number of invalid records 
and duplicates found in the input files; a total of 80,394 substances were imported.  
 
The QSAR software applied in the screening can handle organic substances with an unambiguous 
structure, i.e. so-called discrete organics (no mixtures/UVCB’s, organometallics, inorganics), which 
are: 
• Containing at least two carbon atoms  
• Containing only H, Li, B, C, N, O, F, Na, Mg, Si, P, S, Cl, K, Ca, Br, or I  
• In reality not mixtures with two or more “big components” when hydrolysed 
 
Therefore, subsequent processing included hydrolysis simulation, exclusion of inorganic substances 
as well as substances with only one carbon atom, mixtures, generic structures, structures containing 
heavy and other inacceptable atoms or inappropriate ions, and structures with valency errors:  
 
Database Manager hydrolysis simulator generates, among others, the following flags and 
parameters: 
MOL._WEIGHT: if MOL._WEIGHT is not defined, the structure may be incorrect or too complex. 
Calc_Trace_Wrong_SMILES: The SMILES has minor problems 
Calc_Trace_Too_Long: The SMILES is too long 
 
Combinations of these: 
No Calc_Trace warnings and MOL._WEIGHT is defined: The structure is OK for Database Manager 
No Calc_Trace warnings and MOL._WEIGHT is not defined: The structure contains a generic atom 
('R') or cannot be interpreted by Database Manager 
 
Calculation SMILES was generated stripping off ions for substances where this was found 
appropriate, in order to facilitate the QSAR prediction of these substances:  
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Calculation SMILES generation assigns the following mutually exclusive flags: 
Calc_OK_Discrete - calculation SMILES generated OK and the structure is discrete 
Calc_OK_Mixture - calculation SMILES generated OK, the structure can be a mixture 
none - the calculation SMILES is not ok 
 
In order to exclude low quality structures and/or ones containing generic atoms, structures flagged 
with 'SMILES too long' and structures flagged with 'Calc_Trace warning' AND 'MOL._WEIGHT not 
defined' were removed. These filterings resulted in 72,308 structures.  
 
Finally, structures that were ok for the substance database platform but not accepted by the QSAR 
prediction software (MultiCASE) were removed.  
 
The total number of substances suitable for prediction was 70,983. 
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Annex 3 MultiCASE 
MultiCASE is a commercial artificial intelligence software system. In the creation of a model, the 
program analyses a training set of substances with known activity and starts by dividing each 
substance into fragments containing 2–10 interconnected atoms (non-hydrogen atoms). These 
fragments are labelled with the experimental value of the parent substance. MultiCASE determines 
the distribution of all fragments among the substances in the training set. The distribution of the 
fragments is assumed to be binomial. If a fragment is over-represented (p>95%) in the group of 
active or inactive substances the fragment is assumed to be relevant for the modelled activity. If the 
fragment is not significantly overrepresented in active or inactive substances it will not be 
considered important. A fragment with a statistical correlation to active or inactive substances is 
called a biophore or a biophobe, respectively. When all fragments have been examined for their 
importance to activity, a hierarchical selection takes place, starting with the biophore with the most 
statistically significant result. Substances containing this substructure are set aside and the next 
biophore is found in the same manner. This is repeated until either the entire training set is used or 
there are no more statistically significant fragments. The whole procedure is then performed for 
biophobes in an identical way. Each group of substances containing a biophore or biophobe is then 
analysed to find modulators that either enhance or decrease the probability of the fragment being a 
biophore/biophobe. The modulators can be structural fragments or chemical properties (e.g. 
activating fragments, deactivating fragments, log Kow, molecular orbital energies, volume / surface 
descriptors) /18/.  
 
When a model is developed and MultiCASE predicts the activity for a substance, the program first 
looks for biophores contained in the substance. If it identifies a biophore it then looks for 
modulators to calculate the activity of the substance. When MultiCASE predicts the activity of 
substances it produces a system of output values, which can be further processed to define 
unambiguous positive, negative and equivocal outcomes. Positive means that the model predicts 
that if this substance would be tested, e.g. in the Ames test, the results would likely be positive for 
Ames mutations, i.e. the substance would be an Ames mutagen. The opposite goes for the negative 
predictions. Equivocal means that a definite call could not be made, as it can also happen in 
experimental tests. An equivocal was not seen as reliable and was not used in the cross-validation. 
 
The applicability domains for MultiCASE models as defined by the US Food and Drug 
Administration (FDA) /14/ and implemented in the MultiCASE software were used in this project. 
This means that no warnings in the predictions were accepted, except warning for one unknown 
fragment in substances where a significant biophore had been detected. A compound was only 
predicted as positive/active if it contained at least one statistically significant biophore. Only 
positive predictions where no significant deactivating fragments were detected were accepted. 
 
The data was entered into MultiCASE using SMILES notations (without stereochemical 
information).  
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Annex 4 Details on individual 
models 
Reverse mutation test, Ames in vitro (internal id: AGA) 
• Endpoint: The bacterial reverse mutation test detects point mutations, which involve 
substitution, addition or deletion of one or a few DNA base pairs, as described in the 
OECD test guideline 471. 
• Source: Developed by the DTU Food QSAR group in the MultiCASE software based on 
data from Kazius et al. /19/ 
• Technical data: The training set consists of 4102 substances, 2299 positive and 1803 
negative. Cross-validation by 5 times twofold 50% gave: sensitivity 84%, specificity 83% 
and concordance 84%. 
 
Chromosome aberration in CHO (Chinese Hamster Ovary) in vitro (internal id: A61) 
• Endpoint: The chromosome aberration tests identifies agents that cause structural 
chromosome aberrations in cultured mammalian cells, as described in the OECD test 
guideline 473. 
• Source: Commercial MultiCASE model A61 /20/  
• Technical data: The training set consists of 233 substances, 95 positive, 4 marginal and 134 
negative. DTU cross-validation by 5 times twofold 50% gave: sensitivity 32%, specificity 
91% and concordance 70%. 
 
Chromosome aberration in CHL (Chinese Hamster Lung) in vitro (internal id: AN6) 
• Endpoint: The chromosome aberration tests identifies agents that cause structural 
chromosome aberrations in cultured mammalian cells, as described in the OECD test 
guideline 473. Chromosome damage is expressed as breakage of single or both chromatids, 
sometimes followed by reunion between chromatids or of both chromatids at an identical 
site.  
• Source: Developed by the DTU Food QSAR group in the MultiCASE software, and based 
on data from Sofuni /21, 22/ and described in /23/. 
• Technical data: The training set consists of 600 substances, 294 positive and 306 negative. 
Cross-validation by 5 times twofold 50% gave: sensitivity 58%, specificity 87% and 
concordance 74%. 
 
Mouse lymphoma in vitro; Mammalian Cell Gene Mutation Test measured by TK (internal id: AN1) 
• Endpoint: The mammalian cell gene mutation test in mouse lymphoma cells detects 
mutations affecting the heterozygous thymidine kinase (TK) locus, as described in the 
OECD. It identifies substances acting as clastogens (delete, add, or rearrange chromosome 
sections) as well as point mutagens.  
• Source: Developed by the DTU Food QSAR group in the MultiCASE software, and based 
on data from /24/. 
• Technical data: The training set consists of 555 substances, 282 positive, 22 marginal and 
251 negative. Cross-validation by 5 times twofold 50% gave: sensitivity 69%, specificity 
86% and concordance 79%. 
 
Rodent dominant lethal in vivo (internal id: AN4) 
• Endpoint: The rodent dominant lethal test identifies major genetic damage, mainly the 
induction of structural and numerical chromosomal anomalies, as described in the OECD 
test guideline 478. Early embryonic deaths is the most significant index of dominant 
lethality and as such used as endpoint 
• Source: Developed by the DTU Food QSAR group in the MultiCASE software, and based 
on data from /25/. 
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• Technical data: The training set consists of 191 substances, 78 positive and 113 negative. 
Cross-validation by 5 times twofold 50% gave: sensitivity 41%, specificity 95% and 
concordance 76%. 
 
Sex-Linked Recessive Lethal test in Drosophila melanogaster in vivo (internal id: AN5) 
• Endpoint: The Drosophila melanogaster SLRL (Sex-Linked Recessive Lethal) test detects 
the occurrence of mutations, point mutations and small deletions, in the germ line of the 
insect, as described in the OECD test guideline 477.  
• Source: Developed by the DTU Food QSAR group in the MultiCASE software, and based 
on data from /26/. 
• Technical data: The training set consists of 377 substances, 190 positive and 187 negative. 
Cross-validation by 5 times twofold 50% gave: sensitivity 74%, specificity 88% and 
concordance 82%. 
 
SCE Mouse in vivo (internal id: ANB) 
• Endpoint: The Mouse SCE (Sister Chromatid Exchange) assay detects interchange of DNA 
between two sister chromatids of a duplicating chromosome.  
• Source: Developed by the DTU Food QSAR group in the MultiCASE software, and based 
on data from /27/. 
• Technical data: The training set consists of 265 substances, 103 positive and 162 negative. 
Cross-validation by 5 times twofold 50% gave: sensitivity 71%, specificity 87% and 
concordance 86%. 
 
Mouse mammalian bone marrow erythrocyte micronucleus in vivo (internal id: ANC) 
• Endpoint: The Mouse micronucleus assay detects micronuclei produced by damage to the 
chromosomes or the mitotic apparatus in red blood cells, as described in the OECD test 
guideline 474.  
• Source: Developed by the DTU Food QSAR group in the MultiCASE software, and based 
on data from /28-31/. 
• Technical data: The training set consists of 358 substances, 168 positive and 190 negative. 
Cross-validation by 5 times twofold 50% gave: sensitivity 30%, specificity 85% and 
concordance 66%. 
 
Comet assay in vivo (internal id: ANE) 
• Endpoint: The Comet assay detects DNA strand break and can be applied to virtually any 
organ of interest.  
• Source: Developed by the DTU Food QSAR group in the MultiCASE software, and based 
on data from /32/ plus a number of physiological substances theoretically assumed not to 
have the effect (such as various amino acids, sugar molecules, fatty acids etc.), which were 
included to get a better distribution between positives and negatives in the training set for 
the model. 
• Technical data: The training set consists of 286 substances, 136 positive and 150 negative. 
Cross-validation by 5 times twofold 50% gave: sensitivity 63%, specificity 93% and 
concordance 84%. 
 
FDA cancer models in vivo  
• Endpoint: The cancer test development of tumours, as described in the OECD test 
guideline 451. In the experimental test, the test substance is administered by an 
appropriate route to the animals for a major portion of their lifespan. The highest dose 
level should elicit signs of toxicity, without substantially altering the normal lifespan due to 
effects other than tumours. 
• Source: Commercial MultiCASE open models AF1-AF4 and models including proprietary 
data AG1-AG4, and based on data from the NTP (US National Toxicology Program) rodent 
carcinogenicity database, the Lois Gold Carcinogen Potency Database, FDA/CDER (US 
Food and Drug Administration / Center for Drug Evaluation and Research) archives, and 
the scientific literature. The proprietary (confidential) data constitute around ten percent 
of the training sets in AG1-AG4. The open models are solely based on the non-proprietary 
data part /33/. 
• Technical data:  
• AG1: Male Rat incl. proprietary data: The training set consists of 1381 substances. Cross-
validation cannot be performed as part of the training set is hidden for the user. (The open 
part of the model, corresponding to the model AF1 was cross-validated: The training set 
consists of 1277 substances, 590 positive, 92 marginal and 595 negative. DTU cross-
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validation by 5 times twofold 50% gave: sensitivity 44%, specificity 77% and concordance 
69%.) 
 AG2: Female Rat incl. proprietary data: The training set consists of 1376 substances. 
Cross-validation cannot be performed as part of the training set is hidden for the user. 
(The open part of the model, corresponding to the model AF2 was cross-validated: The 
training set consists of 1274 substances, 546 positive, 64 marginal and 664 negative. DTU 
cross-validation by 5 times twofold 50% gave: sensitivity 42%, specificity 83% and 
concordance 74%.) 
 AG3: Male Mouse incl. proprietary data: The training set consists of 1252 substances. 
Cross-validation cannot be performed as part of the training set is hidden for the user. 
(The open part of the model, corresponding to the model AF3 was cross-validated: The 
training set consists of 1157 substances, 495 positive, 67 marginal and 595 inactive. DTU 
cross-validation by 5 times twofold 50% gave: sensitivity 47%, specificity 83% and 
concordance 76%.) 
 AG4: Female Mouse incl. proprietary data: The training set consists of 1263 substances. 
Cross-validation cannot be performed as part of the training set is hidden for the user. 
(The open part of the model, corresponding to the model AF4 was cross-validated: The 
training set consists of 1169 substances, 526 positive, 58 marginal and 585 inactive. DTU 
cross-validation by 5 times twofold 50% gave: sensitivity 42%, specificity 82% and 
concordance 74%.) 
 The total suite of models were validated by external validation with 100 substances which 
gave overall; sensitivity 59%, specificity 98% and concordance 75% 
 
RCA call 
 For a substance to be positive according to the RCA methodology there have to be two or 
more positive carcinogenicity predictions within AG1-4, where only predictions for 
substances without significant deactivating fragments are accepted /14/.  
 
Teratogenicity FDA TERIS (internal id: A49) 
 Endpoint: Teratogenic potential in humans 
 Source: Commercial MultiCASE model A49 based on data from the US Teratogen 
Information System (TERIS) and a database based on the US Food and Drug 
Administration guidelines/34/. 
 Technical data: The training set consists of 323 substances, 130 positives and 193 
negatives. DTU cross-validation by 5 times twofold 50% gave: sensitivity 50%, specificity 
91% and concordance 79%. 
 
 
 
 
 
Annex 5 QSAR CMR predicted PRS not 
registered in 2012, illustrative cases 
Identity QSAR CMR1 – Danish 
QSAR Database 
QSAR predictions – other 
models2 
Use3, exposure & C&L eChemPortal4  
1-Propene, 3-isothiocyanato-  
(allyl isothiocyanate) 
 
CAS RN 57-06-7 
 
 
 
 
 
CMR 
Based on positive predictions 
in models for Ames (part of 
the training set), CA CHO 
(part of training set), 
Drosophila m. SLRL (part of 
training set), and FDA RCA 
cancer call based on male rat 
(part of training set) and 
female rat (part of training 
set). 
Cancer 
Benigni-Bossa carcinogenicity 
(TOXTREE, v.1.0.0) = positive (good 
reliability)   
Mutagenicity 
CAESAR mutagenicity model 
(v.2.1.12) = positive (good reliability) 
T.E.S.T mutagenicity consensus 
model = positive 
Benigni-Bossa mutagenicity 
(TOXTREE, v.1.0.0) = positive (good 
reliability)   
Reproductive toxicity 
T.E.S.T developmental toxicity 
consensus model = positive 
Use: Naturally in seeds from 
mustard and produced 
synthetically. Used e.g. as 
pesticide, as a flavouring agent in 
foods (on EU flavouring 
substances list), as a fumigant, in 
ointments and mustard plasters 
and as a military poison gas. 
SPIN: Narrow range of 
applications in DK (4-10) (last 
record from 2010). One or several 
uses indicate a potential for direct 
exposure to humans (consumer 
and occupational). Total tonnage 
in DK: 0.2 Tonnes (last record 
from 2003). 
 
ECHA C&L Inventory: Total 
number of notifiers: >500. No self-
classifications for CMR. 
 
NTP: Carcinogenic in male rats and 
equivocal in female rats. Not carcinogenic in 
mice of either sex (MTD probably not 
reached).  
 
IARC: not classifiable as to its 
carcinogenicity to humans (Group 3), 
limited evidence for the carcinogenicity to 
experimental animals. Not teratogenic to 
mice, rats, hamsters or rabbits, but 
resorptions were seen in mice and rats.  
 
US NJ RTK Hazardous Substance Fact 
Sheet; may damage the developing foetus. 
NTP: In vivo; positive SCE, negative 
Drosophila SLRL and negative/equivocal 
CA; in vitro; positive CA CHO, ML and SCE, 
and weakly positive/negative Ames. 
1 The underlying QSAR models for the resulting positive C, M or R call are listed. QSAR models in the CMR algorithms which are not mentioned may either have given negative predictions or the chemical may have been out of 
the applicability domain. No information is included about the manual evaluations of the predictions or information from other CMR relevant models and systems applied. 
2 Predictions generated in CMR models in CAESAR, TOXTREE, SarPy and T.E.S.T. Obtained predictions with reported low reliability or outside applicability domain are not reported. 
3 Quick Google searches and the US EPA ACTOR site primarily used to find information. 
4 The experimental results listed in this column are the non-comprehensive results of a quick look-up. 
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Identity QSAR CMR1 – Danish 
QSAR Database 
QSAR predictions – other 
models2 
Use3, exposure & C&L eChemPortal4  
1,3-Propanediol, 2-methyl-2-propyl-
, dicarbamate (Meprobamate) 
 
CAS RN 57-53-4 
 
 
 
R 
Based on positive 
prediction/test in model for 
human teratogenicity (part of 
training set). 
CAESAR developmental toxicity 
model (v.2.1.6) = positive (good 
reliability)  
T.E.S.T developmental toxicity 
consensus model = Positive (part of 
training set) 
Use: Anxiolytic drug launched in 
1955. EMA has recommended 
suspension in 2012 due to serious 
side effects (confusion, loss of 
consciousness).  
SPIN: Not recorded in DK. Very 
narrow range of applications in SE 
(1-3) (last record from 2010). One 
or several uses indicate a potential 
for direct exposure to humans 
(consumer and occupational). 
Total tonnage in SE: not recorded. 
ECHA C&L Inventory: Total 
number of notifiers: 26. No self-
classifications for CMR. 
 
UMD list; recognized developmental 
toxicant.  
Methanesulfonic acid, methyl ester 
(Methyl methanesulfonate) 
 
CAS RN 66-27-3 
 
 
CMR 
Based on positive predictions 
in models for Ames (part of 
training set), CA CHL (part of 
training set), mouse 
lymphoma (part of training 
set), Drosophila m. SLRL 
(part of training set), mouse 
micronucleus (part of training 
set), Rodent dominant lethal 
(part of training set), mouse 
SCE (part of training set), 
mouse Comet (part of 
training set), and FDA cancer 
Cancer 
No predictions within AD obtained 
Mutagenicity 
CAESAR mutagenicity model 
(v.2.1.12) = positive (good reliability) 
T.E.S.T mutagenicity consensus 
model = positive (part of training set) 
Reproductive toxicity 
T.E.S.T developmental toxicity 
consensus model = positive 
Use: Research chemical 
SPIN: Intermediate range of 
applications in DK (11-32) (last 
record from 2010). One or several 
uses indicate a very probable 
direct exposure to humans 
(consumer and occupational). 
Total tonnage in DK: not recorded. 
ECHA C&L Inventory: Total 
number of notifiers: 29. 
• 24 have self -classified 
as carc. 1 B 
• 1has self-classified as 
US EPA ACTOR: An alkylating agent in 
cancer therapy that may also act as a 
mutagen by interfering with and causing 
damage to DNA.  
CPDB Mouse TD50: 31.8 mg/kg. 
 
IARC; Increased frequency of resorptions 
and congenital malformations. Induced 
mouse germ cell mutations and 
chromosomal aberrations, and DNA 
damage, micronuclei, sister chromatid 
exchanges and chromosomal aberrations in 
somatic cells of rodents in vivo. Increased 
the frequency of DNA damage, gene 
Use of QSAR to identify potential CMR substances of relevance under the REACH regulation 29 
 
Identity QSAR CMR1 – Danish 
QSAR Database 
QSAR predictions – other 
models2 
Use3, exposure & C&L eChemPortal4  
male mouse (part of training 
set). 
Mut 1B, Carc 1b & Rep 2 
• 1 has self-classified as 
Mut 2 & Carc 1 A 
• 3 have not self-classified 
for CMR 
mutation, sister chromatid exchanges and 
micronuclei in human and rodent cell 
cultures, as well as chromosomal 
aberrations in rodent cells in vitro. Induced 
somatic and sex-linked mutations in 
Drosophila. Was mutagenic in bacteria. Is 
probably carcinogenic to humans (Group 
2A) 
 
 
Benzenesulfonic acid, 4-methyl-, 
ethyl ester 
(ethyl toluene-4-sulphonate) 
 
CAS RN 80-40-0 
 
 
 
MR 
Based on positive predictions 
in models for Drosophila m. 
SLRL, mouse micronucleus, 
mouse SCE, and mouse 
Comet. 
Mutagenicity 
CAESAR mutagenicity model 
(v.2.1.12) = positive (good reliability) 
SarPy model (v.1.0.6) = positive 
(good reliability) 
T.E.S.T mutagenicity consensus 
model = positive (part of training set) 
Benigni-Bossa mutagenicity 
(TOXTREE, v.1.0.0) = negative (good 
reliability) 
Reproductive toxicity 
T.E.S.T developmental toxicity 
consensus model = positive 
Use: No information found 
SPIN: Not recorded in DK. Very 
narrow range of applications in SE 
(1-3) (last record from 2010). No 
indication of exposure to humans. 
Total tonnage in SE: not recorded. 
ECHA C&L Inventory: Total 
number of notifiers: 38. No self-
classifications for CMR. 
 
Gene-tox: Positive Ames and other in vitro 
tests (SHE cell transformation, DNA repair, 
Human UDS), negative in vitro forward and 
reverse gene mutation. 
CCRIS; negative / weakly positive Ames, 
and positive ML and MN in vitro.  
9,10-Anthracenedione, 1-
(methylamino)-(1-
(methylamino)anthraquinone) 
 
CAS RN 82-38-2 
CM 
Based on positive predictions 
in models for Ames, mouse 
lymphoma, Mouse SCE, 
mouse Comet, and FDA RCA 
cancer call based on male rat 
Cancer 
CAESAR carcinogenicity model 
(v.2.1.8)  = positive (good reliability) 
Benigni-Bossa carcinogenicity 
(TOXTREE, v.1.0.0) = positive (good 
Use: Dye known as disperse red 9. 
Used in coloured smoke and in 
manufacture of rubber and plasstic 
products. 
SPIN: Very narrow range of 
applications in DK (1-3) (last 
No CMR relevant information has been 
identified. 
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Identity QSAR CMR1 – Danish 
QSAR Database 
QSAR predictions – other 
models2 
Use3, exposure & C&L eChemPortal4  
 
and female rat. reliability) 
Mutagenicity 
CAESAR mutagenicity model 
(v.2.1.12) = positive (good reliability) 
SarPy model (v.1.0.6) = positive 
(good prediction)  
T.E.S.T mutagenicity consensus 
model = positive 
Benigni-Bossa mutagenicity 
(TOXTREE, v.1.0.0) = positive (good 
reliability) 
record from 2010). One or several 
uses indicate a potential for direct 
exposure to consumers and a very 
probable potential for 
occupational exposure. Total 
tonnage in DK: 1 Tonne (last 
record from 2007). 
 
ECHA C&L Inventory: Total 
number of notifiers: >1000. No 
self-classifications for CMR. 
 
 
1H-Indene-1,3(2H)-dione, 2-(2-
quinolinyl)- 
 
CAS RN 83-08-9 
 
 
CR 
Based on positive predictions 
in models for Ames (part of 
training set), CA CHL, mouse 
lymphoma (part of training 
set), FDA RCA cancer call 
based on male rat (part of 
training set) and female rat 
(part of training set), and 
human teratogenicity. 
Cancer 
Benigni-Bossa carcinogenicity 
(TOXTREE, v.1.0.0) = negative (low 
reliability) – however, part of training 
set (dataset ID: 681),  experimental 
value = positive 
Reproductive toxicity 
CAESAR developmental toxicity 
model (v.2.1.6) = positive (good 
reliability) 
T.E.S.T developmental toxicity 
consensus model = positive 
Use: Pigment. Used in industrial 
coatings, plastics, decorative 
paints. 
 
SPIN: Not recorded in DK. Very 
narrow range of applications in 
NO (1-3) (last record from 2010). 
One or several uses indicate a 
probable exposure to humans. 
Total tonnage in NO: not recorded. 
ECHA C&L Inventory: No records 
 
No CMR relevant information has been 
identified (except as mentioned in previous 
columns the experimental data in the model 
training sets). 
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Identity QSAR CMR1 – Danish 
QSAR Database 
QSAR predictions – other 
models2 
Use3, exposure & C&L eChemPortal4  
2H-1-Benzopyran-2-one (coumarin) 
 
CAS RN 91-64-5 
 
 
CMR 
Based on positive predictions 
in models for Ames (part of 
training set), CA CHO (part of 
training set), mouse 
lymphoma, mouse 
micronucleus, mouse SCE, 
FDA RCA cancer call based on 
male rat (part of training set), 
female rat (part of training 
set), male mouse (part of 
training set) and female 
mouse (part of training set), 
and human teratogenicity 
(part of training set). 
Cancer 
CAESAR carcinogenicity model 
(v.2.1.8) = positive (domain warning) 
Benigni-Bossa carcinogenicity 
(TOXTREE, v.1.0.0) = positive (good 
reliability) (part of training set) 
Mutagenicity 
CAESAR mutagenicity model 
(v.2.1.12) = positive (good reliability) 
(part of training set) 
SarPy model (v.1.0.6) = negative (low 
reliability) (part of training set. 
Experimental value = positive)  
T.E.S.T mutagenicity consensus 
model = negative (part of training set. 
experimental value = positive)  
Benigni-Bossa mutagenicity 
(TOXTREE, v.1.0.0) = positive (good 
reliability) 
Reproductive toxicity 
CAESAR developmental toxicity 
model (v.2.1.6) =  positive (good 
reliability (part of training set) 
T.E.S.T developmental toxicity 
consensus model = negative (part of 
training set. experimental value = 
positive) 
Use: Fragrant found in many 
plants. Used as flavouring agent in 
food, cosmetics and tobacco, 
anticoagulant precursor. 
SPIN: Very wide range of 
applications in DK (>100) (last 
record from 2010). One or several 
uses indicate a very probable 
exposure to humans (consumer 
and occupational). Total tonnage 
in DK: 0.1 Tonnes (last record 
2010). However, 38 Tonnes are 
reported from SE (2009). 
ECHA C&L Inventory: Total 
number of notifiers: >1000.  
• 86 notifiers have self-
classified as Carc 2 
• The remaining notifiers 
have not self-classified for 
CMR 
CPDB Rat TD50 39.2 mg/kg/d, Mouse 
TD50 103 mg/kg/d.  
IARC; limited evidence in experimental 
animals for carcinogenicity; not classifiable 
as to its carcinogenicity to humans (Group 
3), and no signs of teratogenicity in mice, 
rats, rabbits or miniature pigs. 
 
UMD; listed as a teratogen and a mutagen 
in the "Dangerous Properties of Industrial 
Materials", 7th Ed., by N. Irving Sax and 
Richard J. Lewis. 
 
NTP; negative in Drosophila SLRL and MN 
in vivo (peripheral blood), positive in Ames 
and positive in vitro in CHO SCE, and 
weakly positive in vitro in CHO CA. 
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Identity QSAR CMR1 – Danish 
QSAR Database 
QSAR predictions – other 
models2 
Use3, exposure & C&L eChemPortal4  
Naphthalene, 2-methoxy- 
 
CAS RN 93-04-9 
 
 
 
M 
Based on positive predictions 
in models for mouse 
micronucleus, mouse SCE, 
and mouse Comet. 
CAESAR mutagenicity model 
(v.2.1.12) = positive (domain 
warning) 
T.E.S.T mutagenicity consensus 
model = positive 
 
Use: Impurity of Naproxen 
SPIN: Very wide range of 
applications in DK (>100) (last 
record from 2010). One or several 
uses indicate a very probable 
exposure to humans (consumer 
and occupational). Total tonnage 
in DK: < 0.1 Tonnes (last record 
2010).  
ECHA C&L Inventory: Total 
number of notifiers >1000. No 
self-classifications for CMR.  
 
No CMR relevant information has been 
identified.  
Naphthalene, 2-ethoxy- 
 
CAS RN 93-18-5 
 
 
 
M 
Based on positive predictions 
in models for mouse 
micronucleus, mouse SCE, 
and mouse Comet. 
CAESAR mutagenicity model 
(v.2.1.12) = positive (domain 
warning) 
SarPy model (v.1.0.6) = negative 
(domain warning) 
T.E.S.T mutagenicity consensus 
model = positive 
 
Use: No information found 
SPIN: Very wide range of 
applications in DK (>100) (last 
record from 2010). One or several 
uses indicate a very probable 
exposure to humans (consumer 
and occupational). Total tonnage 
in DK: 0.1 Tonnes (last record 
2010).  
ECHA C&L Inventory: Total 
number of notifiers >1000. No 
self-classifications for CMR.  
 
CCRIS: Negative Ames. 
Butane, 1-bromo- 
 
CAS RN 109-65-9 
 
C 
Based on positive predictions 
in models for Ames, mouse 
CAESAR carcinogenicity model 
(v.2.1.8) = negative (domain 
warning) 
Use: No information found 
SPIN: Not recorded in DK. Very 
narrow range of applications in SE 
CCRIS: Positive Ames, negative MN in 
vitro.  
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Identity QSAR CMR1 – Danish 
QSAR Database 
QSAR predictions – other 
models2 
Use3, exposure & C&L eChemPortal4  
 
 
lymphoma, and FDA RCA 
cancer call based on male rat, 
female rat, male mouse and 
female mouse. 
 (1-3) (last record from 2010). One 
or several uses indicate a potential 
exposure to consumers and a 
probable exposure to workers. 
Total tonnage in SE: confidential 
(an old record exist with 10 tonnes 
in SE in 1999). 
ECHA C&L Inventory: Total 
number of notifiers: 129. No self-
classifications for CMR.  
Cinchonan-9-ol, 6'-methoxy-, 
monohydrochloride, (8alpha,9R)-  
(Quinine hydrochloride) 
 
CAS RN 130-89-2 
 
 
 
MR 
Based on positive predictions 
in models for Drosophila m. 
SLRL, mouse SCE (part of 
training set), mouse Comet, 
and human teratogenicity 
(part of training set). 
Mutagenicity 
No predictions within AD obtained 
Reproductive toxicity 
No predictions within AD obtained 
Use: Naturally in cinchona tree 
bark and produced synthetically. 
Used as 
antimalarial,analgesic,anti-
inflammatory; flavouring agent in 
beverages. 
SPIN: Not recorded in DK. Very 
narrow range of applications in SE 
(1-3) (last record from 2010). One 
or several uses indicate a potential 
exposure to consumers and 
workers. Total tonnage in SE: 
confidential. 
ECHA C&L Inventory: Total 
number of notifiers: 798. No self-
classifications for CMR. 
GENE-TOX: MN (Mammalian 
polychromatic erythrocytes) in vitro 
positive, SCE in vivo positive. 
CCRIS: Positive Ames (E.Coli). 
EDSPDB Reproductive Toxicity Ranking; 
limited study showed teratogenic effects in 
rats. 
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Identity QSAR CMR1 – Danish 
QSAR Database 
QSAR predictions – other 
models2 
Use3, exposure & C&L eChemPortal4  
Benz[b]indeno[1,2-d]pyran-
3,4,6a,9,10(6H)-pentol, 7,11b-
dihydro-, cis-(+)- 
(Haematoxylin) 
 
CAS RN 517-28-2 
 
 
CR 
Based on positive predictions 
in models for CA CHL, FDA 
RCA cancer call based on 
male rat (part of training set), 
female rat (part of training 
set), and human 
teratogenicity.  
Cancer 
CAESAR carcinogenicity model 
(v.2.1.8) = positive (good reliability) 
(part of training set, experimental 
value = positive) 
Benigni-Bossa carcinogenicity 
(TOXTREE, v.1.0.0) = negative (low 
reliability), however, part of training 
set, experimental value = positive) 
Reproductive toxicity 
CAESAR developmental toxicity 
model (v.2.1.6) = positive (domain 
warning)  
T.E.S.T developmental toxicity 
consensus model = positive 
Use: Extracted from logwood tree. 
Used as histology stain. 
SPIN: Very narrow range of 
applications in DK (1-3) (last 
record from 2010). One or several 
uses indicate a potential for direct 
exposure to consumers and a very 
probable potential for 
occupational exposure. Total 
tonnage in DK: confidential (last 
record from 2010). 
 
ECHA C&L Inventory: Total 
number of notifiers: 33. No self-
classifications for CMR. 
CPDB: Rat TD50 1000 mg/kg/d (hmo(B)), 
no test in mouse. 
CCRIS: Negative Ames tests. 
 
 
Benzene, 1-bromo-4-
(bromomethyl)- 
(alpha,p-Dibromotoluene) 
 
CAS RN 589-15-1 
 
 
C 
Based on positive predictions 
in models for mouse 
lymphoma, FDA RCA cancer 
call based on male rat , female 
rat, male mouse, and female 
mouse. 
No predictions within AD obtained Use: No information found 
SPIN: Not recorded in DK. Very 
narrow range of applications in 
NO (1-3) (last record from 2010). 
One or several uses indicate a 
potential exposure to consumers. 
Total tonnage in NO: confidential. 
ECHA C&L Inventory: Total 
number of notifiers: 38. No self-
classifications for CMR. 
 
CCRIS: Negative Ames tests. 
1-Propanol, 2,3-dichloro- 
 
C 
Based on positive predictions 
No predictions within AD obtained Use: Production of 
epichlorohydrin 
No CMR relevant information has been 
identified. 
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Identity QSAR CMR1 – Danish 
QSAR Database 
QSAR predictions – other 
models2 
Use3, exposure & C&L eChemPortal4  
CAS RN 616-23-9 
 
 
 
in models for Ames (part of 
training set), CA CHO, CA 
CHL (part of training set), 
mouse lymphoma, and FDA 
RCA cancer call based on 
female rat, male mouse and 
female mouse.  
SPIN: Very narrow range of 
applications in DK (1-3) (last 
record from 2010). One or several 
uses indicate a potential exposure 
to workers. Total tonnage in DK: 
confidential. 
ECHA C&L Inventory: Total 
number of notifiers: 53.  
• 1 self-classification for 
Mut 2 
• 52 notifiers without self-
classifications for CMR 
 
Benzenamine, 4-[(4-
aminophenyl)(4-imino-2,5-
cyclohexadien-1-ylidene)methyl]-2-
methyl-, monohydrochloride 
(Magenta I) 
 
CAS RN 632-99-5 
 
 
 
C 
Based on positive predictions 
in models for Ames (part of 
training set), mouse 
lymphoma, and FDA RCA 
cancer call based on female 
rat, male mouse and female 
mouse. 
No predictions within AD obtained Use: Magenta dye. Textile dye; 
bacteria stain. 
SPIN: Very narrow range of 
applications in DK (1-3) (last 
record from 2010). One or several 
uses indicate a potential exposure 
to consumers and workers. Total 
tonnage in DK: <0.1 Tonnes (last 
record from 2010). 
ECHA C&L Inventory: Total 
number of notifiers: 103. 
• 3 have self-classified as 
Carc. 1 A 
• 1 has self-classified as 
Carc. 1 B 
IARC: Magenta containing CI Basic Red 9 is 
possibly carcinogenic to humans (Group 
2B).  
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Identity QSAR CMR1 – Danish 
QSAR Database 
QSAR predictions – other 
models2 
Use3, exposure & C&L eChemPortal4  
• 61 have self-classified as 
Carc. 2 
• 38 have not self-classified 
for CMR 
9,10-Anthracenedione, 1,4-
bis(methylamino)- 
 
CAS RN 2475-44-7 
 
 
 
CM 
Based on positive predictions 
in models for Ames, mouse 
lymphoma, mouse SCE, 
mouse Comet, and FDA RCA 
cancer call based on male rat 
and female rat. 
Cancer 
CAESAR carcinogenicity model 
(v.2.1.8) = positive (good prediction) 
Benigni-Bossa carcinogenicity 
(TOXTREE, v.1.0.0) = positive (good 
prediction) 
Mutagenicity 
CAESAR mutagenicity model 
(v.2.1.12) = positive (good reliability) 
SarPy model (v.1.0.6) = positive 
(good reliability) 
T.E.S.T mutagenicity consensus 
model = positive 
Benigni-Bossa mutagenicity 
(TOXTREE, v.1.0.0) = positive (good 
prediction) 
Use: No information found 
SPIN: Very narrow range of 
applications in DK (1-3). Narrow 
range of applications in SE (4-10) 
(last record from 2010). One or 
several uses indicate a probable 
exposure to consumers and 
workers. Total tonnage in DK: <0.1 
Tonnes (last record from 2010). 
ECHA C&L Inventory: Total 
number of notifiers: 47. No self-
classifications for CMR.  
 
 
No CMR relevant information has been 
identified. 
1,3-Propanediol, 2,2-
bis(bromomethyl)- 
 
CAS RN 3296-90-0 
 
C 
Based on positive predictions 
in models for Ames (part of 
training set), mouse 
lymphoma, and FDA RCA 
CAESAR carcinogenicity model 
(v.2.1.8) = positive (good prediction) 
(part of training set, experimental 
value = positive) 
Benigni-Bossa carcinogenicity 
Google: Flame retardant 
SPIN: Very narrow range of 
applications in DK (1-3). Narrow 
range of applications in SE (4-10) 
(last record from 2010). One or 
HPVIS: Positive Ames, CA in vitro and MN 
in vivo; negative SCE in mammalian cells in 
vitro. Increased tumor incidence at multiple 
sites in rats and mice. Female-specific 
decrease in reproductive capacity in mice. 
IARC: Possibly carcinogenic to humans 
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Identity QSAR CMR1 – Danish 
QSAR Database 
QSAR predictions – other 
models2 
Use3, exposure & C&L eChemPortal4  
 
 
cancer call based on male rat 
(part of training set), female 
rat (part of training set), male 
mouse (part of training set), 
and female mouse (part of 
training set). 
(TOXTREE, v.1.0.0) = positive (good 
prediction) (part of training set, 
experimental value = positive) 
 
several uses indicate a potential 
exposure to consumers (DK) and a 
very probable exposure to workers 
(SE). Total tonnage in DK: 
confidential. 
ECHA C&L Inventory: Total 
number of notifiers: 116.  
• 85 have self-classified as 
Carc 1B and Mut 1B 
• 30 have self-classified as 
Carc 2 
• 1 has not classified for 
CMR 
(Group 2B) 
1-Naphthalenemethanol, 
alpha,alpha-bis[4-
(dimethylamino)phenyl]-4-
(phenylamino)- 
(Solvent Blue 4) 
 
CAS RN 6786-83-0 
 
 
 
MR 
Based on positive predictions 
in models for rodent 
dominant lethal mouse SCE 
and mouse Comet. 
Mutagenicity 
T.E.S.T mutagenicity consensus 
model = positive 
Reproductive toxicity 
T.E.S.T developmental toxicity 
consensus model = positive 
Use: Used in inks and dyes 
SPIN: Very narrow range of 
applications in DK & SE (1-3) (last 
record from 2010). One or several 
uses indicate a probable exposure 
to workers (DK) and a very 
probable exposure to consumers 
and workers (SE). Total tonnage in 
DK: confidential. Total tonnage in 
SE: 1 Ton (last record from 2010). 
ECHA C&L Inventory: Total 
number of notifiers: 77.  
• 1 has self-classified as Carc 
1A 
• 2 have self-classified as 
No CMR relevant information has been 
identified. 
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Identity QSAR CMR1 – Danish 
QSAR Database 
QSAR predictions – other 
models2 
Use3, exposure & C&L eChemPortal4  
Carc 1b and Mut 2 
• 1 has self-classified as Carc 
2 and Mut 2 
• 73 have not self-classified 
as CMR 
 
1H-Naphth[2,3-f]isoindole-
1,3,5,10(2H)-tetrone, 4,11-diamino-
2-(3-methoxypropyl)- 
(C.I. Disperse Blue 60) 
 
CAS RN 12217-80-0 
 
 
CM 
Based on positive predictions 
in models for Ames, CA CHL, 
mouse lymphoma, mouse 
micronucleus, mouse SCE, 
and FDA RCA cancer call 
based on male rat and female 
rat. 
Cancer 
Benigni-Bossa carcinogenicity 
(TOXTREE, v.1.0.0) = positive (good 
reliability) 
Mutagenicity 
CAESAR mutagenicity model 
(v.2.1.12) = positive (domain 
warning) 
T.E.S.T mutagenicity consensus 
model = positive 
Benigni-Bossa mutagenicity 
(TOXTREE, v.1.0.0) = positive 
(domain warning) 
Use: Textile dye 
SPIN: Very narrow range of 
applications in DK (1-3) and no 
indication of exposure to humans 
(last record from 2008). Very 
narrow range of applications in 
NO and one or several uses 
indicate a very probable exposure 
to consumers (last record from 
2010). Total tonnage in NO: 
confidential. 
ECHA C&L Inventory: Total 
number of notifiers: 92. No self-
classifications for CMR.  
 
No CMR relevant information has been 
identified. 
Oxirane, 2,2'-[(1-
methylethylidene)bis(4,1-
cyclohexanediyloxymethylene)]bis- 
 
CAS RN 13410-58-7 
 
 
CMR  
Based on positive predictions 
in models for Ames, CA CHO, 
CA CHL, mouse lymphoma,  
Drosophila m. SLRL, mouse 
Comet, FDA RCA cancer call 
based on male rat, female rat, 
Cancer 
No predictions within AD obtained 
Mutagenicity 
CAESAR mutagenicity model 
(v.2.1.12) = equivocal (domain 
warning) 
Use: Derivative of BPA (Bisphenol 
A). Used in epoxy resins; food and 
beverage cans. 
SPIN: No records from DK. Very 
narrow range of applications in SE 
(1-3) (last record from 2010). One 
or several uses indicate a potential 
No CMR relevant information has been 
identified. 
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Identity QSAR CMR1 – Danish 
QSAR Database 
QSAR predictions – other 
models2 
Use3, exposure & C&L eChemPortal4  
 male mouse and female 
mouse. 
SarPy model (v.1.0.6) = positive 
(domain warning) 
T.E.S.T mutagenicity consensus 
model = positive 
Reproductive toxicity 
CAESAR developmental toxicity 
model (v.2.1.6) =  positive (domain 
warning) 
T.E.S.T developmental toxicity 
consensus model = negative 
exposure to consumers and 
workers. Total tonnage in SE: 
confidential. 
ECHA C&L Inventory: Total 
number of notifiers: 51. No self-
classifications for CMR.  
 
Oxirane, 2,2'-[1,4-
cyclohexanediylbis(methyleneoxym
ethylene)]bis- 
 
CAS RN 14228-73-0 
 
 
CMR 
Based on positive predictions 
in models for Ames, CA CHO, 
CA CHL, mouse lymphoma,  
Drosophila m. SLRL, mouse 
Comet, FDA RCA cancer call 
based on male mouse and 
female mouse. 
Cancer 
No predictions within AD obtained 
Mutagenicity 
CAESAR mutagenicity model 
(v.2.1.12) = positive (good reliability) 
SarPy model (v.1.0.6) = positive 
(good reliability) 
T.E.S.T mutagenicity consensus 
model = positive 
Benigni-Bossa mutagenicity 
(TOXTREE, v.1.0.0) = positive 
(domain warning) 
Reproductive toxicity 
T.E.S.T developmental toxicity 
consensus model = negative 
Use: Used in epoxy resins 
SPIN: Narrow range of 
applications in DK (4-10) (last 
record from 2010). One or several 
uses indicate a probable exposure 
to workers. Total tonnage in DK: 
0.5 Tonnes (last record from 
2010). An old record exists with 28 
tonnes in DK in 2003. 
ECHA C&L Inventory: Total 
number of notifiers: 396. No self-
classifications for CMR.  
No CMR relevant information has been 
identified. 
Propanamide, 2,3-dibromo- 
 
C 
Based on positive predictions 
No predictions within AD obtained Use: Research chemical 
SPIN: No records from DK. Very 
No CMR relevant information has been 
identified. 
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Identity QSAR CMR1 – Danish 
QSAR Database 
QSAR predictions – other 
models2 
Use3, exposure & C&L eChemPortal4  
CAS RN 15102-42-8 
 
 
 
in models for Ames, and FDA 
RCA cancer call based on 
male rat, female rat, male 
mouse and female mouse. 
narrow range of applications in SE 
(1-3) (last record from 2010). One 
or several uses indicate a potential 
exposure to consumers and a 
probable exposure to workers. 
Total tonnage in SE: confidential. 
ECHA C&L Inventory: Total 
number of notifiers: 29. No self-
classifications for CMR. 
 
Oxirane, 2,2'-
[methylenebis(phenyleneoxymethyl
ene)]bis- 
 
CAS RN 39817-09-9 
 
 
CMR 
Based on positive predictions 
in models for Ames, CA CHO, 
CA CHL, mouse lymphoma,  
Drosophila m. SLRL, mouse 
SCE, mouse Comet, FDA RCA 
cancer call based on male rat, 
female rat, male mouse and 
female mouse. 
Cancer 
Benigni-Bossa carcinogenicity 
(TOXTREE, v.1.0.0) = positive 
(domain warning) 
Mutagenicity 
CAESAR mutagenicity model 
(v.2.1.12) = positive (domain 
warning) 
SarPy model (v.1.0.6) = positive 
(domain warning) 
T.E.S.T mutagenicity consensus 
model = positive 
Benigni-Bossa mutagenicity 
(TOXTREE, v.1.0.0) = positive 
(domain warning) 
Reproductive toxicity 
T.E.S.T developmental toxicity 
consensus model = positive 
Use: Derivative of BPF (Bisphenol 
F). Used in epoxy resins; food and 
beverage cans. 
SPIN: No records from DK. 
Narrow range of applications in SE 
(4-10) (last record from 2010). 
One or several uses indicate a very 
probable exposure to workers. 
Total tonnage in SE: <0.1 tonnes. 
An older record exists with 43 
tonnes in DK in2003. 
ECHA C&L Inventory: Total 
number of notifiers: 81. No self-
classifications for CMR. 
 
No CMR relevant information has been 
identified. 
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Identity QSAR CMR1 – Danish 
QSAR Database 
QSAR predictions – other 
models2 
Use3, exposure & C&L eChemPortal4  
1,4-Methanonaphthalen-6(2H)-one, 
octahydro-7-methyl- 
 
CAS RN 41724-19-0 
 
 
 
R 
Based on positive prediction 
in model for human 
teratogenicity. 
CAESAR developmental toxicity 
model (v.2.1.6) = positive (good 
reliability) 
T.E.S.T developmental toxicity 
consensus model = negative 
Use: Fragrance agent 
SPIN: Very narrow range of 
applications in DK (1-3) (latest 
record from 2010). One or several 
uses indicate a potential exposure 
to consumers and workers. Total 
tonnage in DK: confidential. 
ECHA C&L Inventory: Total 
number of notifiers: 900. No self-
classifications for CMR. 
 
No CMR relevant information has been 
identified. 
Cyclopropanecarboxylic acid, 3-
(2,2-dichloroethenyl)-2,2-dimethyl-
, ethyl ester 
 
CAS RN 59609-49-3 
 
 
 
C 
Based on positive predictions 
in models for Ames, mouse 
lymphoma,  FDA RCA cancer 
call based on male mouse and 
female mouse. 
No predictions within AD obtained Use: No information found 
SPIN: No records from DK. Very 
narrow range of applications in 
SE(1-3) (latest record from 2010). 
One or several uses indicate a 
probable exposure to workers and 
consumers. Total tonnage in SE: 
confidential. 
ECHA C&L Inventory: Total 
number of notifiers: 23. No self-
classifications for CMR. 
 
No CMR relevant information has been 
identified. 
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Identity QSAR CMR1 – Danish 
QSAR Database 
QSAR predictions – other 
models2 
Use3, exposure & C&L eChemPortal4  
Oxirane, 2,2'-[[2-ethyl-2-
[(oxiranylmethoxy)methyl]-1,3-
propanediyl]bis(oxymethylene)]bis- 
 
CAS RN 3454-29-3 
 
 
CMR 
Based on positive predictions 
in models for Ames, CA CHO, 
CA CHL, mouse lymphoma,  
Drosophila m. SLRL mouse 
Comet, FDA RCA cancer call 
based on male mouse and 
female mouse. 
Cancer 
CAESAR carcinogenicity model 
(v.2.1.8) = positive (domain warning) 
 Mutagenicity 
CAESAR mutagenicity model 
(v.2.1.12) = positive (good reliability) 
SarPy model (v.1.0.6) = positive 
(good reliability) 
T.E.S.T mutagenicity consensus 
model = positive 
Reproductive toxicity 
CAESAR developmental toxicity 
model (v.2.1.6) = negative (domain 
warning)  
T.E.S.T developmental toxicity 
consensus model = positive 
Use: Used in epoxy resins. 
SPIN: No records from DK. 
Narrow range of applications in SE 
& NO (4-10). One or several uses 
indicate a potential exposure to 
consumers and a very probable 
exposure to workers. Total 
tonnage: 1.1 tonnes in SE and 1 
tonne in NO. 
ECHA C&L Inventory: Total 
number of notifiers: 155. No self-
classifications for CMR. 
 
No CMR relevant information has been 
identified. 
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Annex 6 QSAR CMR predicted registered 
substances, illustrative cases 
Identity 
QSAR CMR5 – Danish 
QSAR Database 
QSAR predictions – other 
models6 Use7 and C&L REACH registration and eChemPortal8 
Sodium 2-mercaptobenzothiazole 
(MBT Sodium salt) 
 
CAS RN 2492-26-4 
 
 
C  
 
Based on positive predictions in 
models for CA CHO (part of 
training set), mouse lymphoma 
(part of training set),  FDA RCA 
cancer call based on male rat 
(part of training set), female rat 
(part of training set), and 
female mouse (part of training 
set). 
 
 
No predictions within AD obtained 
 
Use: Corrosion inhibitor in 
automobile antifreeze solution, 
thermal stabilizer in silicon fluids, 
preservative in latex paint and on 
wood, and component of 
agricultural pesticides  
 
REACH registration:  
Tonnage: 10,000 – 100,000 
Tonnes/year. 
Only Industrial use. Not self-
classified for CMR. 
REACH registration: four studies are cited. 
Two studies with mixed formulations are 
reported as negative (reliability 4 – not 
assignable). In addition, two studies are 
reported for a structural analogue. These are 
giving indications of some carcinogenic 
effects. 
 
ESIS: HPVC 
IARC: Possibly carcinogenic to humans 
(Group 2B) 
9,10-Anthracenedione 
(Anthraquinone)  
 
CAS RN 84-65-1 
 
C 
Based on positive predictions in 
models for Ames (part of 
training set), mouse lymphoma, 
and FDA RCA cancer call based 
on male rat (part of training 
set), female rat (part of training 
CAESAR carcinogenicity model 
(v.2.1.8) = positive (good reliability)  
Benigni-Bossa carcinogenicity 
(TOXTREE, v.1.0.0) = positive (good 
reliability) (part of training set, 
experimental value = positive) 
Use: Intermediate in the 
manufacture of dyes and pigments; 
bird repellent. 
 
REACH registration:  
Tonnage: 1,000 – 10,000 
Tonnes/year. Industrial and 
REACH registration: The NTP studies are 
cited in the registration dossier. The 
registrant concludes that the effects are not 
sufficient for classification as carcinogenic. 
 
ESIS: HPVC 
CPDB; negative cancer test in mice. 
5 The underlying QSAR models for the resulting positive C, M or R call are listed. QSAR models in the CMR algorithms which are not mentioned may either have given negative predictions or the chemical may have been out of 
the applicability domain. No information is included about the manual evaluations of the predictions or information from other CMR relevant models and systems applied. 
6 Predictions generated in CMR models in CAESAR, TOXTREE, SarPy and T.E.S.T. Obtained predictions with reported low reliability or outside applicability domain are not reported. 
7 Quick Google searches and the US EPA ACTOR site primarily used to find information. 
8 The experimental results listed in this column are the non-comprehensive results of a quick look-up. 
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Identity 
QSAR CMR5 – Danish 
QSAR Database 
QSAR predictions – other 
models6 Use7 and C&L REACH registration and eChemPortal8 
 
 
set), male mouse (part of 
training set) and female mouse 
(part of training set). 
 professional use. Not self-classified 
for CMR. 
 
NTP; clear evidence of cancer in female rats 
and male/ female mouse, and some evidence 
in male rats. 
IARC: In prep. 
Neodecanoic acid, oxiranylmethyl 
ester (selected analogs) 
(2,3-epoxypropyl neodecanoate) 
 
CAS RN 26761-45-5 
 
 
CR  
Based on positive predictions in 
models for Ames, mouse 
lymphoma, Drosophila m. 
SLRL, and FDA RCA cancer call 
based on male rat, female rat, 
male mouse and female mouse. 
Cancer 
No predictions within AD obtained 
Mutagenicity 
CAESAR mutagenicity model 
(v.2.1.12) = equivocal (domain 
warning) (part of training set, 
experimental value = positive) 
SarPy model (v.1.0.6) = positive 
(domain warning (part of training set, 
experimental value = positive) 
T.E.S.T mutagenicity consensus 
model = negative 
Reproductive toxicity 
T.E.S.T developmental toxicity 
consensus model = positive 
Use: A reactive diluent for epoxy 
resins in industrial coatings. 
 
REACH registration:  
Tonnage: 10,000 – 100,000 
Tonnes/year. Industrial and 
professional use. Self-classified as 
MUTA 2 (CLP) (the registration 
dossier was updated with the 
MUTA 2 classification close to the 
publication date for this report). 
 
REACH registration9: According to 
information from the registration dossier the 
substance is mutagenic in-vivo in the TGR 
assay in bone-marrow and liver tissue. Based 
on these results the substance is self classified 
as MUTA 2 (CLP). The data for the male germ 
cell mutant frequencies was incomplete at the 
time of registration. Negative in OECD 486 
(UDS). No carcinogenicity studies are 
available and a testing proposal has been 
submitted for a 2-generation reproductive 
toxicity study and a pre-natal developmental 
toxicity study. 
 
ESIS: HPVC 
HPVIS: Weak positive in CA in vitro and 
positive in Ames, negative for DNA single 
strand damage with single dose in rats. 
9 When the substance was chosen as an illustrative case the registration dossier did not contain the MUTA2 self-classification, which appeared in a later update of the registration dossier. However, it was chosen to keep the 
substance in this table of illustrative QSAR cases. 
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QSAR Database 
QSAR predictions – other 
models6 Use7 and C&L REACH registration and eChemPortal8 
1,6-Hexanediol-diglycidyl ether  
 
CAS RN 16096-31-4 
 
 
C 
Based on positive predictions in 
models for CA CHO, CA CHL, 
and FDA RCA cancer call based 
on female rat, male mouse and 
female mouse. 
 
Cancer 
No predictions within AD obtained 
Mutagenicity 
CAESAR mutagenicity model 
(v.2.1.12) = positive (good reliability)  
SarPy model (v.1.0.6) = positive 
(good reliability) 
T.E.S.T mutagenicity consensus 
model = positive 
Benigni-Bossa mutagenicity 
(TOXTREE, v.1.0.0) =positive 
(domain warning) 
 
Use: In applications such as 
adhesives, civil engineering 
projects, structural composites, 
marine and protective coatings, and 
potting and encapsulation of 
electronic components. 
 
REACH registration:  
Tonnage: 1,000 – 10,000 
Tonnes/year. Industrial, 
professional and consumer use. Not 
self-classified for CMR. 
REACH registration: positive in vitro in 
AMES. However, negative in vivo results in 
OECD TG 486 (UDS in vivo) and 474 (MN in 
vivo). No carcinogenicity studies are 
available. 
 
ESIS: LPVC 
eChemPortal: No CMR relevant information 
Benzenediamine, ar,ar-diethyl-ar-
methyl- (selected analogs) 
(Diethyl toluenediamine) 
 
CAS RN 68479-98-1 
 
    
C  
Based on positive predictions in 
models for Ames, CA CHO, 
mouse lymphoma, and FDA 
RCA cancer call based on male 
mouse and female mouse. 
 
Benigni-Bossa carcinogenicity 
(TOXTREE, v.1.0.0) = positive 
(domain warning) 
 
Use: Chain extender for elastomeric 
polyurethanes and also a curing 
agent for epoxides. 
 
REACH registration:  
Tonnage: 1,000 – 10,000 
Tonnes/year. Industrial and 
professional use. Not self-classified 
for CMR. Has a harmonized 
classification without CMR. 
REACH registration: A carcinogenicity study 
(OECD TG 451) has been carried out.  Some 
effects are described in the robust study 
summary such as a significant increase in 
hepatocellular adenomas in female rats, 
follicular cell adomas and follicular cell 
hyperplasia/follicular cysts in high dose 
females  and thyroid follicular cell adenomas 
in male rats. However,  according to the 
registrant: “The neoplastic outcomes 
paralleled biologically significant decreases 
in body weight, and appeared to be 
secondary to excessive toxicity from 
exceeding the maximum tolerated dose of the 
test substance”. 
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ESIS: HPVC 
eChemPortal: No CMR relevant information 
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 Use of QSAR to identify potential CMR substances of relevance under the REACH regulation 
Substances classified as carcinogenic, mutagenic or toxic for reproduction (CMR) (>1 Ton) should have 
been registered under RECAH by December 2010. However, it is well-known that for low tonnage EU 
industrial substances the majority have few or no experimental CMR test data. QSAR models were applied 
to screen around 68,000 REACH pre-registered substances for CMR properties. The Nordic substance 
register database (SPIN) was used to identify not registered substances where human exposure is likely to 
be significant. The results can serve as an observation list for Industry and can be used by authorities for 
future priority setting for e.g. targeted experimental confirmatory testing and for the REACH registered 
substances for potential inclusion on the EU CORAP list. 
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